Comparative effectiveness and safety of direct oral anticoagulants in obese patients with atrial fibrillation
Background Unlike warfarin direct oral anticoagulants (DOACs) are administered in fixed
doses, which raises concerns of its effectiveness on larger patients. Data from randomized …
doses, which raises concerns of its effectiveness on larger patients. Data from randomized …
Effectiveness and safety of direct oral anticoagulants for stroke prevention in atrial fibrillation patients with extreme obesity
B Elad, N Maman, S Ayalon, LH Goldstein - The American Journal of …, 2023 - Elsevier
Direct oral anticoagulants (DOACs) are a favored treatment to prevent stroke in patients with
atrial fibrillation (AF). There are limited data concerning the efficacy and safety of DOACs in …
atrial fibrillation (AF). There are limited data concerning the efficacy and safety of DOACs in …
[HTML][HTML] Direct oral anticoagulation and severe obesity–One size fits all?
Oral anticoagulation is obligatory in patients with atrial fibrillation (AF) to prevent
thromboembolic stroke. Direct direct oral anticoagulants (DOAC) exhibit improved safety …
thromboembolic stroke. Direct direct oral anticoagulants (DOAC) exhibit improved safety …
Non-vitamin K antagonist oral anticoagulant for atrial fibrillation in obese patients
SY Wang, RP Giugliano - The American Journal of Cardiology, 2020 - Elsevier
Highlights•Obesity is an important risk factor for atrial fibrillation.•Despite “obesity paradox”
in atrial fibrillation, patient weight loss preferred.•Oral anticoagulants may be more …
in atrial fibrillation, patient weight loss preferred.•Oral anticoagulants may be more …
Patients with higher body mass index treated with direct/novel oral anticoagulants (DOAC/NOAC) for atrial fibrillation experience worse clinical outcomes
M Lucijanic, I Jurin, H Jurin, T Lucijanic… - International journal of …, 2020 - Elsevier
Introduction Due to fixed dosing of direct oral anticoagulants (DOACs), uncertainty exists
about their efficacy in a population of obese/overweight patients. Patients and methods We …
about their efficacy in a population of obese/overweight patients. Patients and methods We …
Outcomes of direct oral anticoagulants in atrial fibrillation patients across different body mass index categories
Objectives This study sought to evaluate direct oral anticoagulant (DOAC) outcomes (vs.
warfarin) in patients with atrial fibrillation (AF) across body mass index (BMI) categories …
warfarin) in patients with atrial fibrillation (AF) across body mass index (BMI) categories …
Evaluation of safety and efficacy outcomes of direct oral anticoagulants versus warfarin in normal and extreme body weights for the treatment of atrial fibrillation or …
AR Novak, C Shakowski, TC Trujillo, GC Wright… - Journal of Thrombosis …, 2022 - Springer
Despite evolving evidence, the use of direct oral anticoagulants (DOACs) in patients with
extremes of body weight remains controversial. This study aimed to measure the impact of …
extremes of body weight remains controversial. This study aimed to measure the impact of …
[HTML][HTML] Association of body weight with efficacy and safety outcomes in phase III randomized controlled trials of direct oral anticoagulants: a systematic review and …
Essentials• The association of body weight and patient‐important outcomes remains
unknown.• Phase III randomized controlled trials of direct oral anticoagulants (DOACs) were …
unknown.• Phase III randomized controlled trials of direct oral anticoagulants (DOACs) were …
Oral anticoagulant use in patients with morbid obesity: a systematic review and meta-analysis
Objectives Obesity is associated with increased risks of atrial fibrillation (AF) and venous
thromboembolism (VTE) for which anticoagulation is commonly used. However, data on the …
thromboembolism (VTE) for which anticoagulation is commonly used. However, data on the …